


# LEQVIO® — A SMALL INTERFERING RNA THERAPY THAT SELECTIVELY TARGETS THE LIVER TO REGULATE LDL-C LEVELS IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA

**LEQVIO®**  
(inclisiran) injection  
284 mg/1.5 mL


## HOW IS LDL-C REGULATED?

Cholesterol circulates in plasma within lipoprotein particles.<sup>1,2</sup> Uptake of these particles by the liver is one of several tightly coordinated processes that maintain cholesterol homeostasis.<sup>1</sup>



## HOW LEQVIO WORKS

RNA interference (RNAi) is a biological process that regulates gene expression by inhibiting translation of specifically targeted messenger RNA (mRNA) into proteins.<sup>4</sup> Therapies such as small interfering RNAs (siRNAs) have been developed to mimic the body's process of RNAi.<sup>5</sup> LEQVIO is an siRNA therapy that was assessed for its efficacy and safety as an LDL-C-lowering therapy.<sup>3</sup>



STUDIES HAVE SHOWN LEQVIO TO HAVE HIGH SELECTIVITY FOR THE LIVER WITH REDUCED UPTAKE IN OTHER ORGANS<sup>4</sup>

### INDICATION

LEQVIO injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

### IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please see accompanying LEQVIO full Prescribing Information.

1. Trapani L et al. *World J Hepatol.* 2012;4(6):184-190. 2. Shapiro MD et al. *Circ Res.* 2018;122(10):1420-1438. 3. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 4. Ray KK et al. *N Engl J Med.* 2020;382(16):1507-1519. 5. Khvorova A. *N Engl J Med.* 2017;376(1):4-7.